Pharmaceutical Osimertinib Mesylate Osimertinib Mesylate Powder Azd9291 Material Osimertinib Mesylate

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: D-sung-Osimertinib Mesylate
• Product Name: Osimertinib Mesylate
• Name: Azd9291
• Appearance: Yellow Powder
• Color: Yellow Color
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antineoplastic;Anti-Cancer
• Specific: COA
• Test Method: HPLC UV
• Shelf Life: 2 Years
• CAS No.: 1421373-66-1
• Mf: C29h37n7o5s
• MW: 595.719
• Storage: Normal
• Sample: Avaliable
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 5000kg/Month

Product Description

Pharmaceutical Osimertinib Mesylate Osimertinib Mesylate Powder Azd9291 Material Osimertinib Mesylate 

Product Description

Product Details

Product name	Osimertinib Mesylate
Appearance	Yellow powder
CAS NO.	1421373-66-1
MF	C29H37N7O5S
MW	595.719

Osimertinib (previously known as mereletinib or AZD9291) is a third-generation epidermal receptor tyrosine kinase inhibitor drug.
Osimertinib mesylate is a Kinase Inhibitor. The mechanism of action of osimertinib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor.
As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.

Application&Function

AZD-9291 is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Specification